Listening to the Medtronic earnings call this morning all we could think of is that the company is damn lucky none of the analysts have good memories. It wasn’t that long ago that the company was bragging about how their diabetes franchise would be growing in the mid to high double-digit rates and that their stand-alone CGM would become a billion-dollar product. Unfortunately for the company none of this has come true, not even close.
Here are the numbers;
Fourth Quarter Worldwide Growth Down 2.9%
Year to Date Worldwide Growth +11.7 . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.